AU2012366182B2 - Method of treating diabetes using non-glycosylated apolipoprotein A-IV - Google Patents

Method of treating diabetes using non-glycosylated apolipoprotein A-IV Download PDF

Info

Publication number
AU2012366182B2
AU2012366182B2 AU2012366182A AU2012366182A AU2012366182B2 AU 2012366182 B2 AU2012366182 B2 AU 2012366182B2 AU 2012366182 A AU2012366182 A AU 2012366182A AU 2012366182 A AU2012366182 A AU 2012366182A AU 2012366182 B2 AU2012366182 B2 AU 2012366182B2
Authority
AU
Australia
Prior art keywords
protein
apolipoprotein
apoa
biologically active
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2012366182A
Other languages
English (en)
Other versions
AU2012366182A8 (en
AU2012366182A1 (en
Inventor
Sean Davidson
Patrick Tso
Fei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/021802 external-priority patent/WO2012100010A1/en
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2012366182A1 publication Critical patent/AU2012366182A1/en
Publication of AU2012366182A8 publication Critical patent/AU2012366182A8/en
Application granted granted Critical
Publication of AU2012366182B2 publication Critical patent/AU2012366182B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2012366182A 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein A-IV Expired - Fee Related AU2012366182B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPCT/US2012/021802 2012-01-19
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide
US201261675692P 2012-07-25 2012-07-25
US61/675,692 2012-07-25
PCT/US2012/066314 WO2013109342A1 (en) 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein a-iv

Publications (3)

Publication Number Publication Date
AU2012366182A1 AU2012366182A1 (en) 2014-08-07
AU2012366182A8 AU2012366182A8 (en) 2015-06-18
AU2012366182B2 true AU2012366182B2 (en) 2017-08-17

Family

ID=48799573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012366182A Expired - Fee Related AU2012366182B2 (en) 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein A-IV

Country Status (13)

Country Link
US (1) US9951120B2 (https=)
EP (1) EP2804618B1 (https=)
JP (1) JP6310398B2 (https=)
KR (1) KR20140117565A (https=)
CN (1) CN104066436B (https=)
AU (1) AU2012366182B2 (https=)
BR (1) BR112014017141A2 (https=)
CA (1) CA2860782A1 (https=)
EA (1) EA028230B1 (https=)
HK (1) HK1203823A1 (https=)
IL (1) IL233351A (https=)
MX (1) MX357071B (https=)
WO (1) WO2013109342A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051394B2 (en) 2011-01-19 2015-06-09 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv
JP2015524808A (ja) * 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
US10138469B2 (en) * 2014-06-23 2018-11-27 Toagosei Co., Ltd. Synthetic peptide and use thereof
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
CN112891561A (zh) * 2021-03-09 2021-06-04 百码科技(深圳)有限公司 一种基因治疗脂肪肝的生物药剂及其制备方法
CN113018459A (zh) * 2021-03-09 2021-06-25 百码科技(深圳)有限公司 一种基因治疗减肥的生物药剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015198A1 (fr) * 1992-01-27 1993-08-05 Rhone-Poulenc Rorer S.A. Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
US6729075B2 (en) * 2000-10-19 2004-05-04 Wenger Corporation Audience seating system
BR0310100A (pt) 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
EP2051725A4 (en) * 2006-07-11 2011-06-15 Harkness Pharmaceuticals Inc METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
EP2257814B1 (en) 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
CN103833712B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
BR112013004396A2 (pt) * 2010-08-30 2016-05-17 Hoffmann La Roche alimentação alcalina
US9051394B2 (en) 2011-01-19 2015-06-09 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015198A1 (fr) * 1992-01-27 1993-08-05 Rhone-Poulenc Rorer S.A. Polypeptides derives de l'apolipoproteine aiv humaine, leur preparation et leur utilisation

Also Published As

Publication number Publication date
EA201491369A1 (ru) 2015-03-31
MX357071B (es) 2018-06-22
KR20140117565A (ko) 2014-10-07
US9951120B2 (en) 2018-04-24
BR112014017141A2 (pt) 2019-09-24
WO2013109342A1 (en) 2013-07-25
CN104066436B (zh) 2016-12-14
EP2804618B1 (en) 2018-03-07
AU2012366182A8 (en) 2015-06-18
EA028230B1 (ru) 2017-10-31
WO2013109342A8 (en) 2014-09-04
AU2012366182A1 (en) 2014-08-07
MX2014008829A (es) 2014-10-24
CN104066436A (zh) 2014-09-24
EP2804618A1 (en) 2014-11-26
IL233351A0 (en) 2014-08-31
JP2015506942A (ja) 2015-03-05
US20150011469A1 (en) 2015-01-08
HK1203823A1 (en) 2015-11-06
JP6310398B2 (ja) 2018-04-11
IL233351A (en) 2016-12-29
CA2860782A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
AU2012366182B2 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
US11026995B2 (en) Use of CD24 for lowering low-density lipoprotein cholesterol levels
US9266941B2 (en) Apolipoprotein AIV as an antidiabetic peptide
US11390656B2 (en) Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
AU2012385960B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
EP2708233A1 (en) Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
KR20240137091A (ko) IgA 프로테아제 절단체, IgA 프로테아제 절단체를 포함하는 융합 단백질 및 이의 용도
US9512196B2 (en) Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
US9597376B2 (en) Lipoprotein lipase for treatment of hypertriglyceridemic-related conditions including acute pancreatitis
HK40087762A (zh) Adamts13变体、组合物及其用途
Brunner Insight Into Ca2+ Dependent Lipid Scrambling from the Crystal Structure of a TMEM16 Family Member

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 31 , PAGE(S) 4209 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME UNIVERSITY OF CINCINNATI, APPLICATION NO. 2012366182, UNDER INID (31) CORRECT THE NUMBER TO READ PCT/US2012/021802

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application